Antibody-drug conjugates (ADCs) are designed to selectively deliver a cytotoxic payload to the cancer cell. There are now eight approved ADCs for the treatment of several different cancers and ~80 ADCs in clinical development with over 600 clinical trials, which highlights the exponential growth for this important therapeutic landscape. Past 10 years, the ADC field has been witnessing significant technology improvements with respect to ADC target selection, payload diversity, linker design, site-specific conjugation technology, the use of bi-specific antibodies and combination of therapeutics in developing next generation ADCs. This presentation will summarize many preclinical, translational and clinical strategies to improve the therapeutic index of this novel ADC therapeutic platform, thus by making a paradigm shift in cancer chemotherapy.<br/>

Insights to developing nextgen antibody drug conjugates

ACS Fall 2020 Virtual Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.